a developer of biopharmaceuticals for treatment of autoimmune diseases and cancers
Industry Biotechnology
A.I.dvisor tells us that CANF and LGVN have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CANF and LGVN's prices will move in lockstep.
Ticker / NAME | Correlation To CANF | 1D Price Change % | ||
---|---|---|---|---|
CANF | 100% | -3.86% | ||
LGVN - CANF | 31% Poorly correlated | -1.89% | ||
RNA - CANF | 26% Poorly correlated | -4.82% | ||
ZLAB - CANF | 25% Poorly correlated | -10.95% | ||
UBX - CANF | 23% Poorly correlated | -3.82% | ||
IMTX - CANF | 23% Poorly correlated | -0.47% | ||
More |
Ticker / NAME | Correlation To CANF | 1D Price Change % |
---|---|---|
CANF | 100% | -3.86% |
diseases theme (41 stocks) | 22% Poorly correlated | -3.13% |
drugs theme (254 stocks) | 20% Poorly correlated | -4.03% |
cancer theme (82 stocks) | 18% Poorly correlated | -5.37% |
biopharmaceuticals theme (50 stocks) | 15% Poorly correlated | -4.37% |
biotechnology theme (238 stocks) | 14% Poorly correlated | -4.32% |
More |